Extracellular Traps in Patients Diagnosed With Bacterial Vaginosis, Trichomoniasis, Candidiasis, Noninfectious Vaginitis and Cytolytic Vaginosis.
Ramírez-Ledesma. María G MG; Bermudes-Valencia. Berenice B; Balderas-Parada. Rosa M RM; Salazar-Ramírez. Susana G SG; Reyes-Cortés. Ruth R; Magos-Vázquez. Francisco J FJ; Torres-Hernández. José J JJ; Avila. Eva E EE
Key Findings
- LL‑37‑linked extracellular traps are found in bacterial vaginosis, trichomoniasis, candidiasis, noninfectious vaginitis, and cytolytic vaginosis
- Even asymptomatic women often carry pathogens and show extracellular traps, indicating subclinical infection
- Extracellular traps can help control infection but may also worsen vaginal inflammation
Practical Outcomes
- For DIY health enthusiasts, this highlights that immune traps like LL‑37 are a double‑edged sword in vaginal health. While they may aid infection control, they can also increase inflammation, so any attempts to modulate LL‑37 or trap formation should be approached cautiously and are not yet backed by clear protocols.
Summary
The study shows that the antimicrobial peptide LL‑37, which tags DNA‑based immune traps called extracellular traps, appears in many types of vaginal infections and even in women who feel fine but still have hidden microbes, meaning the body’s trap response is common but can also add to inflammation.
Abstract
Vaginal infections are a public health problem associated with serious health complications due to the exacerbated inflammation they generate. Vaginal inflammation may also occur in some noninfectious processes, such as noninfectious vaginitis and cytolytic vaginosis. Immune system cells respond to infections through various mechanisms, such as the formation of extracellular traps (ETs), which are DNA networks associated with effector proteins. Many pathogens induce ETs formation <i>in vitro</i>, as occurs in some natural infections. A recent report indicates that human vaginal infections <i>in vivo</i> generate ETs. Therefore, in this study, we aimed to identify ETs in samples from 40 donors who were diagnosed with infectious (i.e., bacterial vaginosis, candidiasis and trichomoniasis) and noninfectious (i.e., noninfectious vaginitis and cytolytic vaginosis) vaginal inflammation. We were able to observe ETs by identifying the LL-37 peptide, which is associated with DNA networks. In seven vaginal swabs from the control group (formed by 19 donors without vaginal infection symptoms), we detected at least one pathogen per sample and observed ETs; thus, these donors were considered asymptomatic. The remaining 12 donors were confirmed to be healthy, as their exudates did not present any tested pathogens, sign of inflammation or ETs. ETs in vaginal inflammatory processes can worsen inflammation but may also help control infection.
Study Information
pubmed
2024
2024-10-23T00:00:00.000Z
10.1155/2024/7619416
58